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concern was exclusively over the quality of
the scientific data and conclusions, which
would have been the same whatever the
motivation of the criticism.
Bad science can only undermine our
understanding of nature, and the making
of constructive public policy. The
statement that “commercially vested
interests” (that is, ties to Syngenta/
Novartis) are “central to” criticisms of the
data in ref. 4 is as useless in addressing the
scientific issues as would be an accusation
that these data were tainted by a grudge
between Chapela and his former employer
(the same company). Although our
connections to industry are irrelevant to
the scientific issues, and hence do not
warrant disclosure, we feel compelled to
dispel the mischaracterization of Worthy 
et al.. One of us (M. M.) had TMRI
funding for only one-sixth of his study at
UC Berkeley, and the other’s (J. F.) alleged
link to TMRI relies entirely on someone
else’s former Berkeley association. Both of
us currently have research funding
exclusively from the public sector.
We are not unlike many scientists in that
we have shared research and funding with
industry at some point. In stating that we
have “compromised positions”, Worthy et
al. wrongly imply that private-sector
funding strips us of integrity and legitimacy
in the arena of scientific discourse. Far from
promoting “scientific freedom and balance”,
this presumption tars any scientist who can
be suggested to have worked with the
private sector. The only threat to academic
freedom that seems to have materialized
from the Berkeley/TMRI collaboration is
this attitude towards scientists who might
have industry links.
Matthew Metz*
Johannes Fütterer†
*Department of Microbiology, University of
Washington, Seattle, Washington 98195, USA
†Institute of Plant Sciences, ETH, CH-8092 Zürich,
Switzerland
Kaplinsky replies — I, on behalf of the
authors of our Brief Communication2,
state unequivocally that funding from
TMRI has absolutely nothing to do with
our criticisms. Worthy and co-authors are
incorrect. Two of my co-authors of ref. 2
(Hake and Hay) do not receive any
industry funding. Funding information
for the Freeling lab (Braun, Freeling, Lisch
and N. K.) is transparent and public (see
http://plantbio.berkeley.edu/~freeling/lab
web/fund.html); less than a quarter of it is
from industry.
As Worthy et al. state, Chapela and
Quist are “leading critics” of the TMRI
agreement. Chapela is a board member of
PANNA (http://www.panna.org/panna/
about/board.html#ihc), an advocacy 
group opposing genetically modified
organisms (GMOs). It is a double standard
to accuse us, but not Quist and Chapela, of
a conflict of interest.
Our letter was a critique of poorly
conducted and interpreted science and 
was not pro- or anti-GMO or industry. We
simply corrected what we think is bad
science. Even if we were in the pockets of
industry, Quist and Chapela’s published
results4 would still be artefactual.
Nick Kaplinsky
Department of Plant and Microbial Biology,
University of California , Berkeley, California
94720, USA
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Nature comments:
It is highly unusual for Nature to publish
a paper whose principal conclusion is
shown to be not necessarily false but
unsustainable on the basis of the
reported evidence. The paper was not
formally retracted by its authors or by
Nature. In the circumstances, Nature
considered it appropriate for the record
to make clear to readers its revised view
of its original decision to publish. 
The independence of our editorial
decision-making from partisan anti- or
pro-technology agendas and from
commercial interests is paramount in our
role as a journal. Editor, Nature
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Impact-factor rewards
affect Spanish research
Sir — In Spain, as in Finland1, publication
of research reports in journals with a high
impact factor has since 1989 officially been
part of the national system for evaluating
researchers’ productivity. But unlike the
Finnish system, the Spanish system
rewards individuals rather than
departments or institutions.
As stated in the Spanish parliamentary
record2,3, a bonus is awarded only for
“those articles of scientific worth in
journals of recognized prestige in the field.
As a quality indicator, the relevance of the
medium of dissemination in which each
article was published shall be considered.
In those disciplines for which international
systems of quality of publications exist,
reliance on these systems shall be
obligatory.”
What exactly are these “systems of
quality of publication”? In mathematics
and physics, chemistry, cell and molecular
biology, medicine, natural science,
engineering and architecture, economics
and social science, the law specifies that
“preference shall be given to those contri-
butions consisting of articles in journals of
recognized prestige, which shall be
accepted to mean those that occupy
relevant positions in the lists for science
fields in the Subject Category Listings of the
Journal Citation Reports of the Science
Citation Index (Institute for Scientific
Information [ISI], Philadelphia, PA, USA)”
(ref. 4). For the first four fields, the
National Commission for the Evaluation of
Research Activity (CNEAI) recommends
that articles should be published in
journals that occupy a relevant position in
the pertinent ranking, which is understood
to mean the upper third of the listing
ranked by impact factor. There may,
however, be some flexibility under special
circumstances at the discretion of the
experts. The aim of this reward system is to
improve the quality of Spanish science and
its visibility in journals.
The consequences of this law have been
first, a change in Spanish scientists’
publication habits; second, an increase in
the number of Spanish source items in the
ISI databases5,6; and third, a levelling off of
source items in Spanish bibliographic
databases7. Spanish scientific productivity
has doubled: more than twice as many
papers were published between 1991
(immediately after the system of
publication bonuses was passed into law)
and 1998 compared with the period
1982–1990. The acceleration in national
publication output cannot be attributed to
increased financial support (research
budgets had begun to shrink in real terms
by 1991), international collaboration or
mobility of researchers, nor can it be
attributed to an overall increase in
scientific activity8.
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